Catalog No.
Product Name
Application
Product Information
Citations
-
HIFU Enhancer
Perfluorohexane functions as a HIFU (high-intensity focused ultrasound) enhancer, improving the efficacy and precision of ultrasound therapies while minimizing collateral damage to surrounding tissues. This perfluorocarbon compound has been shown to elevate the levels of heme oxygenase-1 (HO-1) and interleukin-10 (IL-10), thereby exhibiting antioxidant properties. Additionally, perfluorohexane plays a significant role in mitigating lung injury induced by lipopolysaccharide (LPS), making it a valuable tool for research into acute lung injury and related therapeutic applications. -
Endogenous Metabolite
5-Methoxy-DL-tryptophan is an endogenous metabolite that exhibits anti-inflammatory properties. This compound is known to inhibit lipopolysaccharide-induced release of interleukin-6 (IL-6), thereby suggesting its role in inflammatory processes. Its biological activity makes it a valuable tool for research in the context of atherosclerosis and related inflammatory conditions. -
PDE2/CDK2 Inhibitor
Aristolochic acid D is a selective inhibitor of PDE2 with an IC50 of 4.673 μM and CDK2 with an IC50 of 25 μM, derived from Aristolochia indica L. This compound demonstrates significant anti-inflammatory properties while exhibiting a non-carcinogenic and non-nephrotoxic profile. Aristolochic acid D is valuable for research applications focused on inflammation and tumor-related diseases, offering insights into therapeutic strategies. -
PDE4 Inhibitor
Morcamilast is a selective and orally active phosphodiesterase 4 (PDE4) inhibitor, exhibiting IC50 values of 1.28 nM for PDE4A1A, 2.33 nM for PDE4B1, and 1.63 nM for PDE4D2. This compound demonstrates significant anti-inflammatory activity by inhibiting the lipopolysaccharide (LPS)-induced release of pro-inflammatory cytokines, including TNF-α, IL-12/23p40, IL-23, and IL-17A in human peripheral blood mononuclear cells (PBMCs) and T cells. Morcamilast also exhibits antipruritic effects, making it a valuable tool for investigating psoriasis, atopic dermatitis, and various other inflammatory disorders. -
PDE1C Inhibitor
PDE1-IN-9 is a selective inhibitor of phosphodiesterase 1 (PDE1), demonstrating an IC50 of 11 nM for PDE1C. This compound significantly reduces the mRNA expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α, as well as iNOS, while inhibiting the production of nitric oxide (NO) and reactive oxygen species (ROS). PDE1-IN-9 also showcases favorable metabolic stability in rat liver microsomes, making it a valuable tool for studying PDE1-related pathways and inflammatory responses. -
PDE4 Inhibitor
Mesopram is a selective phosphodiesterase (PDE) 4 inhibitor that effectively reduces the synthesis of pro-inflammatory cytokines, including TNF-α and IFN-γ. This compound has shown efficacy in alleviating Dextran sulfate sodium (DSS)-induced colitis in murine models, making it a valuable tool for research in chronic inflammatory diseases. Mesopram can be employed to investigate therapeutic strategies aimed at modulating inflammatory responses. -
PPARγ Modulator
GED 0507-34-Levo is an orally active modulator of PPARγ. This compound effectively downregulates the expression of TGF-β, Smad3, IL-13, and CTGF in colon tissue. GED 0507-34-Levo has demonstrated therapeutic potential in improving symptoms of DSS-induced chronic colitis and associated fibrosis, making it a valuable tool for research in inflammatory bowel diseases and fibrotic disorders. -
AhR Modulator
AhR Modulator-1 (6-MCDF) is a selective and orally active modulator of the aryl hydrocarbon receptor (AhR). This compound demonstrates significant inhibition of metastasis by reducing vascular endothelial growth factor (VEGF) production in prostatic tissues prior to tumor formation. Additionally, AhR Modulator-1 exhibits anti-estrogenic effects in the rat uterus, making it a valuable tool for investigating the roles of AhR in cancer biology and endocrine regulation. -
MAO-A/DYRK1A Inhibitor
Norharmine is a Harmine analogue that functions as an inhibitor of monoamine oxidase A (MAO-A) and dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A). It exhibits weak inhibitory activity against MAO-A and demonstrates certain inhibitory effects on DYRK1A, positioning it as a valuable tool for research in neurobiology and cellular signaling pathways. Norharmine is useful in studies focusing on mood disorders and cognitive functions related to these kinase targets. -
Endogenous Metabolite
Ethyl glucuronide is an endogenous metabolite of ethanol, serving as a reliable biomarker for alcohol exposure. It accumulates in hair, providing a measure of alcohol intake over extended periods. Additionally, ethyl glucuronide acts as an agonist for Toll-like receptor 4 (TLR4), making it relevant in studies of inflammatory responses and alcohol metabolism. -
Histamine H1 Receptor Antagonist/5-Lipoxygenase Inhibitor
UCB-35440 is an orally active antagonist of the histamine H1 receptor and a selective inhibitor of 5-lipoxygenase. It demonstrates significant inhibition of leukotriene B4 (LTB4) formation in human whole blood, as well as a reduction in polymorphonuclear cell infiltration in mouse models. UCB-35440 also effectively inhibits histamine-induced bronchoconstriction and alleviates skin inflammation in guinea pig studies. This compound is suitable for research applications related to asthma and inflammatory skin conditions. -
PDE3/PDE4/PDE5/HRH1 Inhibitor
Fenspiride is a potent inhibitor of phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4), and phosphodiesterase 5 (PDE5), with -log IC50 values of 3.44, 4.16, and approximately 3.8, respectively. Additionally, it acts as an antagonist of the H1-histamine receptor, contributing to its anti-inflammatory properties. Fenspiride is primarily utilized in research related to respiratory diseases, offering insights into mechanisms of action and potential therapeutic applications. -
5-Lipoxygenase Inhibitor
Linetastine is a potent, orally active inhibitor of 5-Lipoxygenase, an enzyme critical in the synthesis of leukotrienes. By inhibiting this pathway, Linetastine demonstrates significant antihistamine activity, effectively reducing leukotriene B4 and C4 release from calcium ionophore-stimulated human leukocytes. This compound is particularly useful in research applications focused on inflammatory processes and allergic responses, providing insights into the modulation of leukotriene-mediated pathways. -
HSP70 Ligand
HSP70 Ligand 1 serves as a ligand for the heat shock protein 70 (HSP70), facilitating the development of PROTAC molecules. This compound is instrumental in synthesizing PROTAC HSP70 Degrader-1, enabling targeted protein degradation studies. It is valuable for researchers investigating HSP70's role in cellular stress responses and therapeutic applications. -
Endogenous Metabolite
Palmitic acid sodium is a long-chain saturated fatty acid that serves as an endogenous metabolite. It has been shown to induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in mouse granulosa cells. This compound is commonly utilized to establish a cell steatosis model, making it valuable for research into metabolic disorders and related cellular mechanisms. -
Combined with Hsp90
AMP-PCP disodium is an ATP analogue that specifically targets the N-terminal domain of Hsp90, exhibiting a dissociation constant (Kd) of 3.8 μM. By binding to Hsp90, AMP-PCP disodium promotes the formation of its active homodimer, facilitating studies on protein folding and maturation. This reagent is valuable for research applications focusing on molecular chaperones and their roles in cellular stress responses. -
HSP Inhibitor
Apatorsen sodium is a 2'-methoxyethyl-modified antisense oligonucleotide targeting Hsp27. It effectively reduces Hsp27 mRNA and protein levels, disrupting stress-induced cytoprotective functions, promoting apoptosis, inhibiting tumor growth, and preventing metastasis. This compound is relevant for research applications in non-small cell lung cancer, castration-resistant prostate cancer, breast cancer, ovarian cancer, and bladder cancer. -
Hsp90-Cdc37 PPI Inhibitor
DDO-5936 is a potent inhibitor of the Hsp90-Cdc37 protein-protein interaction. This compound specifically disrupts the chaperone-client complex, leading to altered protein folding and degradation pathways. Its biological activity makes DDO-5936 a valuable tool for research applications focused on colorectal cancer and other related therapeutic areas. -
HSPA5 Inhibitor
HM03 is a selective inhibitor of HSPA5 (Heat Shock Protein 70kDa, also known as Bip or Grp78). This compound exhibits significant anticancer activity, making it a valuable tool for cancer research. It can be utilized to study the role of HSPA5 in tumor progression and therapeutic resistance, providing insights into potential treatment strategies targeting this chaperone protein. -
HSP Co-Inducer
Arimoclomol is an orally active co-inducer of heat shock proteins (HSP). It functions by enhancing Hsp expression, thereby providing protection to motor neurons through the modulation of protein aggregation and promoting the clearance of misfolded proteins via the proteasome-ubiquitin system. This compound is particularly relevant for research applications concerning Niemann-Pick disease type C, as it effectively crosses the blood-brain barrier, facilitating its therapeutic potential in neurological disorders. -
Hsp90 Inhibitor
Zelavespib hydrochloride is a potent inhibitor of the heat shock protein 90 (Hsp90), exhibiting an IC50 of 51 nM in MDA-MB-468 cancer cell lines. This compound disrupts Hsp90 function, leading to the degradation of client oncoproteins, thereby demonstrating significant potential in cancer research. Zelavespib is utilized in studies focused on the therapeutic targeting of Hsp90 for various malignancies. -
HSP Co-Inducer
Arimoclomol citrate is an orally active co-inducer of heat shock proteins (HSPs). It enhances the expression of HSPs, thereby protecting motor neurons by facilitating the clearance of misfolded proteins via the proteasome-ubiquitin system. This compound is particularly relevant for research applications concerning Niemann–Pick disease type C and studies of neurodegenerative disorders linked to protein aggregation. -
Hsp70 Inhibitor
YM-1 is an orally active inhibitor of the heat shock protein 70 (Hsp70). This compound has been shown to induce apoptosis in HeLa cells while also up-regulating key regulatory proteins such as p53 and p21. Its effects on cell viability and protein expression make YM-1 a valuable tool for studying the role of Hsp70 in cancer biology and therapeutic applications. -
PfHsp90 Inhibitor
Ursolic acid acetate is a triterpenoid compound that inhibits Plasmodium falciparum heat shock protein 90 (PfHsp90) with a binding affinity (KD) of 8.16 μM. It exhibits cytotoxic effects on KB cells, with an IC50 value of 8.4 μM. This compound is suitable for applications in tumor research and antimalarial studies, providing a valuable tool for investigating the role of heat shock proteins in disease mechanisms. -
HSP70 Allosteric Inhibitor
MAL3-101 is a potent allosteric inhibitor of the heat shock protein 70 (HSP70), primarily acting by inhibiting the ATPase activity of HSP70 through disruption of the Hsp40 co-chaperone interaction. This compound has demonstrated significant biological activity in cellular models, making it a valuable tool for investigating the role of HSP70 in muscle invasive bladder cancer (MIBC) research. Researchers can utilize MAL3-101 to explore therapeutic strategies targeting this molecular chaperone in cancer treatment. -
HSP90 Inhibitor
Icapamespib hydrochloride is a selective inhibitor of HSP90, targeting epichaperome assembly with slow dissociation kinetics. This compound effectively disrupts disease-related protein interaction networks, reducing neurotoxic protein aggregation and hindering tumor cell survival signals. Icapamespib hydrochloride is valuable in research focused on neurodegenerative diseases, including Alzheimer's disease, along with various cancers, such as glioblastoma and metastatic breast cancer. -
HSP90 Inhibitor
Icapamespib is a selective inhibitor of HSP90 that effectively disrupts epichaperome formation through non-covalent binding, exhibiting slow dissociation kinetics. This compound is capable of crossing the blood-brain barrier, facilitating the disassembly of abnormal protein interaction networks and reducing neurotoxic protein aggregation. Icapamespib demonstrates potential in research applications focused on neurodegenerative diseases, including Alzheimer’s disease, as well as various cancers such as glioblastoma and metastatic breast cancer. -
Hsp90 Inhibitor
SNX-0723 is a potent Hsp90 inhibitor that exhibits anti-Plasmodium activity. It demonstrates notable binding affinity for human Hsp90 and Plasmodium falciparum Hsp90, with inhibition constants (Kis) of 4.4 nM and 47 nM, respectively. Additionally, SNX-0723 effectively inhibits liver-stage Plasmodium berghei ANKA parasites, with an EC50 value of 3.3 μM, making it a valuable tool for research into malaria treatment and Hsp90-related biological processes. -
HSP60-derived Peptide
DiaPep277 is a 24 amino acid peptide derived from the HSP60 protein, specifically from positions 437-460. This peptide has been shown to halt the progression of β-cell destruction in NOD mice and exerts immune modulatory effects on diabetogenic T cells. DiaPep277 is primarily utilized in research studies focused on diabetes and immune response modulation, making it a valuable tool for understanding autoimmune mechanisms and potential therapeutic interventions. -
HSP70 ATPase Inhibitor
Displurigen (NSC375009) is an HSP70 ATPase inhibitor that specifically targets HSPA8, disrupting the pluripotency of human embryonic stem cells. This compound effectively inhibits the ATPase activity of HSP70 with an IC50 of 225 μM, making it a valuable tool for research in stem cell biology and differentiation processes. Its mechanism of action provides insights into cellular signaling pathways related to stem cell maintenance and development. -
HSP90β Inhibitor
KUNB31 is a selective inhibitor of HSP90β, exhibiting a binding affinity with a Kd value of 0.18 μM. This compound disrupts the function of the HSP90β protein, which is implicated in the maturation and stabilization of client proteins involved in cancer and other diseases. KUNB31 is valuable for research focused on cellular stress responses, protein homeostasis, and therapeutic strategies targeting protein chaperones. -
Hsp90 Inhibitor
Hsp90-IN-37 is a potent inhibitor of heat shock protein 90 (Hsp90), demonstrating a 69% reduction in enzymatic activity. This compound exhibits significant antitumor properties, making it a valuable tool in cancer research. Hsp90-IN-37 can be utilized to explore the role of Hsp90 in cancer cell survival and proliferation, supporting efforts to develop targeted therapies. -
Hsp90 Inhibitor
3-Phenyltoxoflavin is an Hsp90 inhibitor that interacts with the Hsp90-TPR2A complex, exhibiting a dissociation constant (Kd) of 585 nM. This compound demonstrates significant anti-cancer properties, making it a valuable tool for cancer research. Its ability to inhibit Hsp90 function provides insights into the molecular mechanisms of cancer cell growth and survival, supporting studies aimed at developing targeted therapies. -
HSP90 Inhibitor
Hsp90-IN-17 hydrochloride is a potent inhibitor of Heat Shock Protein 90 (HSP90), a chaperone protein involved in protein folding and stabilization. This compound demonstrates significant biological activity by disrupting the chaperoning function of HSP90, leading to the degradation of oncogenic client proteins. Hsp90-IN-17 is primarily used in research applications focused on proliferative diseases, including various cancer types and neurodegenerative disorders, providing insights into therapeutic strategies targeting HSP90. -
HSP Activator
Bimoclomol is an HSP activator that enhances the expression of heat shock proteins, playing a crucial role in cellular stress response. It demonstrates significant protective effects in cardiovascular tissues by promoting cytoprotection and anti-apoptotic mechanisms. Bimoclomol is utilized in research investigating its potential therapeutic applications in ischemic tissue damage and other stress-related conditions. -
HSP90 Inhibitor
HSP90-IN-23 is a potent inhibitor of heat shock protein 90 (HSP90) with an IC50 value of 9 nM. This compound effectively induces apoptosis in tumor cells and successfully arrests the cell cycle in the G0/G1 phase. HSP90-IN-23 is an invaluable tool for cancer research, facilitating the study of HSP90's role in tumorigenesis and potential therapeutic strategies. -
HSP70 Inhibitor
AP-4-139B is a potent inhibitor of HSP70, exhibiting an IC50 of 180 nM against human HSP70. Its mechanism involves direct binding to HSP70, leading to the inhibition of ATPase activity. By facilitating the phosphorylation of Beclin-1, AP-4-139B promotes autophagy. This compound has demonstrated significant antitumor activity in preclinical models of colorectal cancer and pancreatic ductal adenocarcinoma, making it a valuable tool for cancer research. -
Hsp70 Activator
SW02 is a potent Hsp70 activator that enhances ATPase activity with an EC50 of 150 μM. This compound induces the accumulation of total tau and phosphorylated tau (pTau), making it a valuable tool for studying tau pathologies. Its ability to modulate Hsp70 activity is of particular interest in neurodegenerative disease research. -
Hsp90 Inhibitor
HSP90-IN-22 is an inhibitor of heat shock protein 90 (Hsp90) that exhibits significant antiproliferative activity in cancer cells. The compound demonstrates IC50 values of 3.65 μM in MCF7 breast cancer cells and 2.71 μM in SKBr3 breast cancer cells. This compound is valuable for research into cancer cell biology and the therapeutic potential of Hsp90 inhibition in cancer treatment. -
Fluorescently-tethered Hsp90 Inhibitor
HS-27 is a fluorescently-tethered inhibitor targeting Heat Shock Protein 90 (Hsp90), facilitating the assessment of surface Hsp90 expression on intact tissue specimens. Comprising core elements of SNX-5422 linked through a PEG spacer to a fluorescein derivative, HS-27 selectively binds to ectopically expressed Hsp90. This reagent is particularly valuable in breast cancer research, providing a tool for applications involving visualization and treatment strategies. -
Hsp110/sGC Regulator
Hsp110/sGC-modulator-1 is a dual-target regulator that modulates Hsp110 and soluble guanylate cyclase (sGC) activities. This compound demonstrates significant inhibitory effects on cell malignancy and promotes vasodilation, making it valuable for cardiovascular research. Additionally, Hsp110/sGC-modulator-1 mitigates pulmonary vascular remodeling and right ventricular hypertrophy through the suppression of Hsp110, highlighting its potential in therapeutic applications for pulmonary hypertension and related disorders. -
Hsp27 Inhibitor
Apatorsen is a 2'-methoxyethyl-modified antisense oligonucleotide that functions as a Heat Shock Protein 27 (Hsp27) inhibitor. By reducing Hsp27 mRNA and protein levels, Apatorsen disrupts stress-induced cytoprotective mechanisms, promotes apoptosis, inhibits tumor growth, and prevents metastasis. This compound is particularly relevant for research focused on non-small cell lung cancer, castration-resistant prostate cancer, breast cancer, ovarian cancer, and bladder cancer. -
PROTAC Hsp90α Degrader
PROTAC Hsp90α degrader 1 is a selective degrader targeting the heat shock protein 90 alpha (Hsp90α) through the PROTAC (proteolysis targeting chimeras) mechanism. This compound exhibits significant cytotoxic activity against various breast cancer cell lines, including MDA-MB-231, MDA-MB-468, MCF-7, and MX-1, with IC50 values of 51.48 μM, 16.46 μM, 8.93 μM, and 11.95 μM, respectively. PROTAC Hsp90α degrader 1 is valuable for investigating the role of Hsp90α in oncogenesis and developing targeted therapies for breast cancer. -
HSP90 Inhibitor
Aminohexylgeldanamycin (AHGDM) is a potent inhibitor of HSP90, a chaperone protein essential for the proper folding and function of many oncoproteins. This compound exhibits significant antiangiogenic and antitumor activities, making it a valuable tool in cancer research. Its ability to disrupt HSP90 function highlights its potential in the study of tumor biology and therapeutic interventions targeting heat shock proteins. -
HSP90 Inhibitor
CH5015765 is a potent HSP90 inhibitor that targets the N-terminal ATP binding site with a dissociation constant of 3.4 nM. This compound demonstrates significant antiproliferative activity, exhibiting IC50 values of 0.46 μM in HCT116 colorectal cancer cells and 0.57 μM in NCI-N87 gastric cancer cells. CH5015765 is suitable for research applications focused on cancer biology and therapeutic development. -
HSP Activator
Feretoside is a phenolic compound derived from the bark of Eucommia ulmoides, functioning as a heat shock protein (HSP) activator. This compound demonstrates significant cytoprotective activities by enhancing cellular stress response mechanisms. Feretoside is primarily utilized in research applications aimed at studying cellular resilience, neuroprotection, and therapeutic strategies for stress-related disorders. -
HSP90 Inhibitor
HSP90-IN-27 is a potent inhibitor of the heat shock protein 90 (HSP90), which plays a critical role in protein folding and stabilization of client proteins involved in cancer progression. This compound effectively disrupts HSP90 function, leading to the degradation of oncogenic proteins and subsequent inhibition of tumor growth. HSP90-IN-27 is applicable in cancer research, particularly in studies focused on targeted therapies and the molecular chaperone network. -
Hsp60-Hsp10 Inhibitor
[Au(TPP)]Cl is an inhibitor of the Hsp60-Hsp10 complex, which plays a critical role in protein folding and cellular stress responses. This compound demonstrates significant anticancer activity by disrupting the refolding process of misfolded proteins, thereby promoting cell apoptosis in cancerous cells. [Au(TPP)]Cl is valuable for research applications targeting cancer therapy and understanding the molecular mechanisms of chaperone functions. -
Hsp90 Inhibitor
Onalespib lactate is a highly potent inhibitor of heat shock protein 90 (Hsp90) with a Kd of 0.71 nM, demonstrating the capability to cross the blood-brain barrier. This compound effectively inhibits tumor cell proliferation, survival, and migration, while reducing the expression of key signaling proteins such as EGFR, p-EGFR, AKT, P-AKT, ERK1/2, P-ERK1/2, S6, and P-S6. With its significant antitumor activity, Onalespib lactate is particularly relevant for research into non-small cell lung cancer (NSCLC). -
Hsp90 Modulator
Cemdomespib is a potent second-generation modulator of Hsp90, known for its high bioavailability. This compound has demonstrated the ability to enhance sensory function in models of diabetic peripheral neuropathy by inducing Hsp70 levels. Its neuroprotective effects are attributed to the activation of the heat shock response, making it a valuable tool for research into neurodegenerative conditions and related therapeutic interventions.
